Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $3.7 million.

  • Spyre Therapeutics' Change in Account Payables rose 26778.67% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 13856.08%. This contributed to the annual value of -$16.0 million for FY2024, which is 56532.06% down from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Change in Account Payables is $3.7 million, which was up 26778.67% from $23000.0 recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Change in Account Payables high stood at $3.7 million for Q3 2025, and its period low was -$6.5 million during Q1 2024.
  • Over the past 5 years, Spyre Therapeutics' median Change in Account Payables value was -$335000.0 (recorded in 2021), while the average stood at -$693052.6.
  • Per our database at Business Quant, Spyre Therapeutics' Change in Account Payables soared by 2920000.0% in 2021 and then plummeted by 106807.87% in 2024.
  • Spyre Therapeutics' Change in Account Payables (Quarter) stood at $1.5 million in 2021, then plummeted by 340.55% to -$3.5 million in 2022, then skyrocketed by 91.8% to -$287000.0 in 2023, then crashed by 193.73% to -$843000.0 in 2024, then surged by 544.25% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $23000.0 for Q2 2025, and $3.0 million during Q1 2025.